NCT05230810: Clinical Trial of Alpelisib and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Endocrine (Hormone) Therapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients should have received at least two FDA-approved HER2-targeted agents in the course of their disease
Exclusions: Patients with symptomatic brain metastases – see trial for details; Patients with known or suspected leptomeningeal disease

Comments are closed.

Up ↑